Explore 15 articles covering in-depth insights and practical guidance on bioprocess scale-up & biomanufacturing economics.
A step-by-step rollout plan with milestones, owners, and metrics. Focus on data quality, standards alignment, and how to avoid measurement theater.
Comprehensive comparison of batch fermentation, continuous bioprocessing, and cell-free synthesis for commercial biomanufacturing. Continuous processes reduce production costs 20–40% at scale but require $10–50M more in automation infrastructure, while cell-free systems achieve 10x faster development cycles for high-value molecules under $1B annual market size.
End-to-end cost and ROI guide for biomanufacturing scale-up from bench to commercial production. A 200,000-liter fermentation facility typically requires $100–300M capex with 4–8 year payback, while COGS reduction of 30–60% is achievable between pilot (1,000 L) and commercial scale (200,000 L) through yield optimization and process intensification.
The 5–8 KPIs that matter, benchmark ranges, and what the data suggests next. Focus on unit economics, adoption blockers, and what decision-makers should watch next.
A concrete implementation with numbers, lessons learned, and what to copy/avoid. Focus on unit economics, adoption blockers, and what decision-makers should watch next.
An in-depth analysis of the most dynamic subsegments within Bioprocess scale-up & biomanufacturing economics, tracking where momentum is building, capital is flowing, and breakthroughs are emerging.
What's working, what isn't, and what's next, with the trade-offs made explicit. Focus on KPIs that matter, benchmark ranges, and what 'good' looks like in practice.
A comprehensive state-of-play assessment for Bioprocess scale-up & biomanufacturing economics, evaluating current successes, persistent challenges, and the most promising near-term developments.
A practical primer: key concepts, the decision checklist, and the core economics. Focus on implementation trade-offs, stakeholder incentives, and the hidden bottlenecks.
Signals to watch, value pools, and how the landscape may shift over the next 12–24 months. Focus on data quality, standards alignment, and how to avoid measurement theater.
Myths vs. realities, backed by recent evidence and practitioner experience. Focus on KPIs that matter, benchmark ranges, and what 'good' looks like in practice.
Side-by-side analysis of common myths versus evidence-backed realities in Bioprocess scale-up & biomanufacturing economics, helping practitioners distinguish credible claims from marketing noise.
Strategic analysis of value creation and capture in Bioprocess scale-up & biomanufacturing economics, mapping where economic returns concentrate and which players are best positioned to benefit.
A forward-looking assessment of Bioprocess scale-up & biomanufacturing economics trends in 2026, identifying the signals that matter, emerging winners, and red flags that practitioners should monitor.
A practitioner conversation: what surprised them, what failed, and what they'd do differently. Focus on implementation trade-offs, stakeholder incentives, and the hidden bottlenecks.